Clinical Trial Update: A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution [Phase 2]

View source ↗

Summary

A Phase 2 study assessed the safety and tolerability of escalating doses of INS365 ophthalmic solution in patients with Dry Eye Disease, with results completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• INS365 Ophthalmic Solution (INS365)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dry Eye Disease | Phase 2 | Status: COMPLETED